Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 390 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ZILRETTA Clear all

Conditions: Greater Trochanteric Pain Syndrome
Interventions: Triamcinolone Acetonide, Platelet Rich Plasma; Drug · Other
Lead sponsor: C.R.Darnall Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Fort Hood, Texas

Conditions: Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Interventions: FX006 32 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 8
States / cities: Anaheim, California • El Cajon, California • North Hollywood, California + 5 more

Conditions: Acromioclavicular Sprain
Interventions: Lidocaine injection, Corticosteroid Injection, Protein Rich Plasma(PRP) Injection; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Trigger Finger Disorder
Interventions: Triamcinolone, Dexamethasone; Drug
Lead sponsor: Ericka Lawler; Other
Eligibility: 18 Years to 100 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Alopecia Areata
Interventions: Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml, Intralesional Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Dyspareunia
Interventions: Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride, Pelvic Rehabilitation; Drug · Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions: Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy; Drug · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Full-thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions: Ketorolac, Marcaine, Kenalog; Drug
Lead sponsor: Michael Khazzam; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chalazion
Interventions: 5-fluorouracil Injection, Triamcinolone Acetonide, Incision and Curettage, Triamcinolone Acetonide/5-fluorouracil mixture; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis Shoulder, Shoulder Pain
Interventions: Micro Fragmented Adipose Tissue, Corticosteroid injection; Biological
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Adhesive Capsulitis, Frozen Shoulder, Adhesive Capsulitis of Shoulder
Interventions: triamcinolone acetonide extended-release injectable suspension; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Kidney Transplantation, Renal Transplantation
Interventions: Alemtuzumab, MMF, Basiliximab, Short-term Tac, tacrolimus, Belatacept, methylprednisolone; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 30
States / cities: Palo Alto, California • San Francisco, California • Miami, Florida + 23 more

Conditions: Cataract, Surgery, Compliance, Patient, Compliance, Medication, Satisfaction, Patient
Interventions: Dropless Regimen, Standard Regimen; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
Interventions: UCN-01 (7-hydroxystaurosporine); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pelvic Pain
Interventions: Onabotulinumtoxin A, Kenalog; Drug
Lead sponsor: Jamie Bartley, DO; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Osteoarthritis
Interventions: triamcinolone acetonide, saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Eczema
Interventions: hydrogel patch, Triamcinolone (TAC) 0.1% cream; Device · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Sinusitis, Chronic Rhinosinusitis
Interventions: Ethmoid Sinus Spacer; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Savannah, Georgia

Conditions: Plaque Psoriasis, Vitamin D3
Interventions: Triamcinolone, Vitamin D3, Placebo; Drug · Dietary Supplement
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Chronic Rhinosinusitis
Interventions: Chitogel, Nexfoam; Device
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Cough (CC), Laryngeal Disease, Coughing
Interventions: Triamcinolone Acetonide Injectable Suspension, Saline injection; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain

Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone

Intralesional Steroids in the Treatment of Alopecia Areata

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

Frozen Shoulder and Hormone Replacement Therapy

Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections

Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis

ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

Hydrogel Patch for the Treatment of Eczema

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Clinical Evaluation of the Ethmoid Sinus Spacer

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Comparison of Chitodex Gel Vs NexFoam on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis

Efficacy of Intramuscular Steroid Injection for Chronic Cough.